A randomized open label efficacy clinical trial of oral guava leaf decoction in patients with acute infectious diarrhoea

Journal of Ayurveda and Integrative Medicine

G.Geetha Krishnan¹  Tannaz Birdi²  Poonam Daswani²  Sushila Kataria³  Manasi Gholkar³ 

[1] Corresponding author.;Foundation for Medical Research, 84-A, R. G. Thadani Marg, Worli, Mumbai-400018, India;Medanta-The Medicity, Sector-38, Gurugram, Haryana-122001, India;

关键词: Anti-diarrhoeal;    Guava leaf decoction;    Psidium guajava;    Infectious diarrhoea;    Clinical trial;    India;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Diarrhoea is amongst the first ten causes of death and its treatment faces an increased threat of drug resistance. Previous studies on the guava leaf decoction (GLD) revealed its suitability for use in infectious diarrhoea of unknown etiology. Objective: The objective of this trial was to establish efficacy, dose and safety of GLD prepared from the Indian Sardar variety in adults with acute infectious diarrhoea. Methods: The current trial was an open efficacy randomized 5-day, parallel group multi-arm interventional study. Amongst 137 adults (18–60 years) suffering with acute diarrhoea, 109 were included (57% females, 43% males). Three doses of GLD (6-leaf, 10-leaf and 14-leaf) were compared with controls receiving oral rehydration solution. Decrease in stool frequency and improvement in consistency were the outcomes measured. The data was analyzed using ANOVA, Tukey's post-hoc test, Kruscal-Wallis test and Chi-Square test where applicable. Results: The trial showed that the 14-leaf (7.4 g) decoction was the most effective. Administration of the decoction, thrice daily helped the patients regain normalcy in 72 h as opposed to 120 h in controls. Safety of the intervention was reflected by normal levels of haemoglobin, liver and kidney parameters. No adverse events were reported. Conclusion: The 14 leaves decoction was a safe treatment for adult acute uncomplicated diarrhoea of unknown etiology. Moreover due to component synergy and divergent mechanisms of action, it could possibly combat the generation of drug resistance and destruction of gut microbiota. Hence GLD has the potential for development as a first line treatment for diarrhoea. Trial registration: Trial was registered with Clinical Trials Registry - India (CTRI registration number: CTRI/2016/07/007095). The trial was retrospectively registered.

【 授权许可】

Unknown